Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Kyle Gano sold 3,809 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total value of $335,649.08. Following the completion of the sale, the insider now owns 17,595 shares in the company, valued at approximately $1,550,471.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NBIX traded down $0.65 on Thursday, hitting $83.75. 13,081 shares of the company were exchanged, compared to its average volume of 868,714. Neurocrine Biosciences, Inc. has a twelve month low of $64.72 and a twelve month high of $126.98. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of 376.73, a PEG ratio of 2.06 and a beta of 1.89.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.32% and a net margin of 4.68%. The firm had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. During the same period in the previous year, the firm posted $0.07 EPS. Neurocrine Biosciences’s revenue for the quarter was up 39.1% on a year-over-year basis. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 1.77 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Architects Inc grew its stake in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock worth $170,000 after purchasing an additional 1,024 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Neurocrine Biosciences during the 3rd quarter worth $234,000. Dupont Capital Management Corp grew its stake in Neurocrine Biosciences by 160.8% during the 3rd quarter. Dupont Capital Management Corp now owns 12,912 shares of the company’s stock worth $1,588,000 after purchasing an additional 7,961 shares in the last quarter. Opera Trading Capital purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth about $449,000. Finally, Barings LLC purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth about $3,097,000. 97.82% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4132860/neurocrine-biosciences-inc-nbix-insider-kyle-gano-sells-3809-shares.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Read More: How does a reverse stock split work?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.